EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA

Katja Deterding, Chengjian Xu, Kerstin Port, Christopher Dietz-Fricke, Jiang Xun, Benjamin Maasoumy, Markus Cornberg iD, Heiner Wedemeyer

Journal of Viral Hepatitis · 2023-07 · 30 (7) · 597-606

DOI: 10.1111/jvh.13831 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 28.03.2023. Verfasst von Katja Deterding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Hepatitis Delta Virus, Hepatitis D. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bulevirtide (BLV) is an entry inhibitor blocking entry of HBsAg into hepatocytes by interfering with the bile acid transporter Na+‐taurocholate co‐transporting polypeptide. We here investigated if bile acid levels before or during BLV treatment would correlate with HDV RNA declines. We studied 20 patients with compensated HDV infection receiving a daily dose of 2 mg bulevirtide subcutaneously qd for at least 24 weeks. ALT levels improved in all patients including 13/20 patients showing normal ALT values at treatment Week 24. An HDV RNA drop of at least 50% was evident in 20/20 patients at Week 24 including 10 patients showing a ≥ 2 log HDV RNA decline. Elevated bile acid levels were detected already before treatment in 10 patients and further increased during BLV administration with different kinetics. Baseline bile acids were associated with higher transient elastography values ( p = .0029) and evidence of portal hypertension ( p = .0004). Bile acid levels before treatment were associated with HDV RNA declines throughout therapy, but not at Week 24 (rho = −0.577; p = .0078; rho = −0.635, p = .0026; rho = −0.577, p = .0077; rho = −0.519, p = .0191; rho = −0.564, p = .0119 and rho = −0.393, p = .087 at treatment Weeks 2, 8, 12, 16, 20 and 24, respectively). However, bile acid increases during treatment were not associated with HDV RNA or ALT declines at any of the time points. BLV‐induced increases in bile salts do not correlate with HDV RNA declines suggesting that the inhibitory effects of BLV on NTCP differ between blocking bile acid transport and hindering HBsAg entry. If baseline bile salt levels could be useful to predict virological response remains to be confirmed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis Delta VirusHepatitis DHumansRNAHepatitis B Surface AntigensBile Acids and SaltsHepatitis B virusAntiviral AgentsLipopeptides

Stichwörter der Autor:innen

HDV RNAantiviral treatmentbile acidsbulevirtidehepatitis delta

Substanzen

RNAHepatitis B Surface AntigensBile Acids and SaltsAntiviral AgentsbulevirtideLipopeptides

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Center for Individualized Infection Medicine, CiiM, a joint venture between Hannover Medical School and the Helmholtz Center for Infection Research, Hannover, Germany.
  • TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • German Centre for Infection Research (DZIF), Hannover-Braunschweig, Germany.
  • D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917).
  • Excellence Cluster Resist, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Markus Cornberg

Zitieren

APA

Deterding, K., Xu, C., Port, K., Dietz-Fricke, C., Xun, J., Maasoumy, B., Cornberg, M., & Wedemeyer, H. (2023). Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. Journal of Viral Hepatitis, 30(7), 597-606. https://doi.org/10.1111/jvh.13831

Vancouver

Deterding K, Xu C, Port K, Dietz-Fricke C, Xun J, Maasoumy B, et al. Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. Journal of Viral Hepatitis. 2023;30(7):597-606. doi:10.1111/jvh.13831

BibTeX
@article{Deterding2023,
  author = {Deterding, Katja and Xu, Chengjian and Port, Kerstin and Dietz-Fricke, Christopher and Xun, Jiang and Maasoumy, Benjamin and Cornberg, Markus and Wedemeyer, Heiner},
  title = {Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA},
  journal = {Journal of Viral Hepatitis},
  year = {2023},
  volume = {30},
  number = {7},
  pages = {597--606},
  doi = {10.1111/jvh.13831}
}
Kostenlos starten →